Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the Phase 3 GRAVITI study
Efficacy and safety results of SC guselkumab in East Asian participants with moderately to severely active CD reflect findings from the global study.
Authors
- Wenjia Liu (ORCID: https://orcid.org/0000-0002-5502-0709)
- Jennifer Fable
- Mobolaji Olurinde
- Qian Cao (ORCID: https://orcid.org/0000-0002-2040-2942)
- Bryan Wahking (ORCID: https://orcid.org/0000-0001-6016-8209)
- Keira Joann Herr (ORCID: https://orcid.org/0000-0003-1322-6407)
- Ken Takeuchi (ORCID: https://orcid.org/0000-0002-3483-1801)
- Tae Oh Kim
- Jianmin Zhuo
- Tadakazu Hisamatsu
- Hong Guo
Institutions
- Johnson & Johnson (United States) (US)
- Chongqing University (CN)
- Kyorin University (JP)
- Sir Run Run Shaw Hospital (CN)
- Johnson & Johnson (Singapore) (SG)
- Inje University Haeundae Paik Hospital (KR)
- Johnson Electric (China) (CN)
- Changzhou No.2 People's Hospital (CN)
- Changzhou Third People's Hospital (CN)
- First People's Hospital of Chongqing (CN)
- Kashiwa Municipal Hospital (JP)
Publication Details
- Journal
- Intestinal Research
- Published
- 2026-02-12
- DOI
- https://doi.org/10.5217/ir.2025.00107
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00